Currently, the RAF/MEK/ERK pathway stands out as a promising and clinical significance target and several RAF and MEK inhibitors are in the stage of preclinical or clinical evolution, such as the combination of trametinib with dabrafenib is approved by the FDA for advanced melanoma [13]. The gene discussed is MAP2K7; the disease is melanoma.